MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Novavax Interest Expense 2011-2026 | NVAX
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Novavax
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 40.6 M | 40.4 M | 37.9 M | 11 M | 21.1 M | 15.1 M | 13.6 M | 13.6 M | 14.1 M | 13 M | 241 K | 157 K | 160 K | 32 K | 9 K |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 40.6 M | 9 K | 14.7 M |
Quarterly Interest Expense Novavax
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9.18 M | 11.9 M | 10.1 M | - | 15.9 M | 7.73 M | 3.65 M | - | -2.98 M | 5.53 M | 4.32 M | - | 4.17 M | 6.23 M | 4.88 M | - | 5.18 M | 5.97 M | 4.84 M | - | 4.46 M | 3.4 M | 3.4 M | - | 3.4 M | 3.4 M | 3.4 M | - | 3.4 M | 3.4 M | 3.4 M | - | 3.52 M | 3.52 M | 3.51 M | - | 3.51 M | 3.51 M | 2.43 M | - | 64 K | 26 K | 36 K | - | 47 K | 51 K | 52 K | - | 64 K | 45 K | 22 K | - | 6 K | 3 K | 3 K | - | 2 K | 2 K | 2 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.9 M | -2.98 M | 3.3 M |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Benitec Biopharma
BNTC
|
-126 K | $ 10.98 | -4.52 % | $ 452 M |  USA |
 |
Ascendis Pharma A/S
ASND
|
80.6 M | $ 221.88 | -0.87 % | $ 5 B |  Danmark |
 |
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M |  Germany |
 |
Milestone Pharmaceuticals
MIST
|
2.55 M | $ 1.36 | -20.0 % | $ 45.5 M |  Canada |
 |
Pharming Group N.V.
PHAR
|
10 K | $ 15.36 | -0.71 % | $ 7.59 B |  Niderland |
 |
I-Mab
IMAB
|
722 K | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
4.68 M | - | 2.54 % | $ 160 B |  France |
 |
Inventiva S.A.
IVA
|
12.2 M | $ 5.78 | -4.3 % | $ 138 M | France |
 |
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | USA |
 |
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | USA |
 |
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | USA |
 |
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | USA |
 |
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | USA |
 |
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | USA |
 |
Assembly Biosciences
ASMB
|
117 K | $ 28.46 | 3.45 % | $ 319 M | USA |
 |
Avenue Therapeutics
ATXI
|
294 K | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
9.29 M | $ 1.37 | -4.2 % | $ 350 M |  Britain |
 |
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | USA |
 |
Axsome Therapeutics
AXSM
|
-15.9 M | $ 156.92 | -1.23 % | $ 7.81 B | USA |
 |
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.4 | -3.68 % | $ 1.02 B | Canada |
 |
Atreca
BCEL
|
3 K | - | -11.76 % | $ 5.79 M | USA |
 |
BioDelivery Sciences International
BDSI
|
-6 K | - | -4.8 % | $ 255 M | USA |
 |
BeiGene, Ltd.
BGNE
|
-42.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
BioMarin Pharmaceutical
BMRN
|
15.3 M | $ 54.13 | -1.64 % | $ 10.4 B | USA |
 |
Calithera Biosciences
CALA
|
2.65 M | - | -10.95 % | $ 876 K | USA |
 |
Cara Therapeutics
CARA
|
3.59 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
2.7 M | - | - | $ 3.74 B | USA |
 |
Compugen Ltd.
CGEN
|
281 K | $ 2.09 | -0.95 % | $ 195 M |  Israel |
 |
Coherus BioSciences
CHRS
|
9 M | $ 1.52 | -5.59 % | $ 178 M | USA |
 |
Checkpoint Therapeutics
CKPT
|
344 K | - | - | $ 169 M | USA |
 |
Clovis Oncology
CLVS
|
444 K | - | -7.23 % | $ 13 M | USA |
 |
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
1.24 M | $ 8.6 | -3.8 % | $ 115 M | USA |
 |
Curis
CRIS
|
890 K | $ 0.77 | 1.89 % | $ 4.86 M | USA |
 |
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | USA |